2021
National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States
Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD, Eby Y, Fernandez RE, Desai NM, Miller J, Bismut GA, Kirby CS, Schmidt HA, Clarke WA, Seisa M, Petropoulos CJ, Quinn TC, Florman SS, Huprikar S, Rana MM, Friedman-Moraco RJ, Mehta AK, Stock PG, Price JC, Stosor V, Mehta SG, Gilbert AJ, Elias N, Morris MI, Mehta SA, Small CB, Haidar G, Malinis M, Husson JS, Pereira MR, Gupta G, Hand J, Kirchner VA, Agarwal A, Aslam S, Blumberg EA, Wolfe CR, Myer K, Wood RP, Neidlinger N, Strell S, Shuck M, Wilkins H, Wadsworth M, Motter JD, Odim J, Segev DL, Durand CM, Tobian AAR, Piquant D, Link K, Hemmersbach-Miller M, Pearson T, Turgeon N, Lyon G, Kitchens W, Huckaby J, Lasseter A, Elbein R, Roberson A, Ferry E, Klock E, Cochran W, Morrison M, Rasmussen S, Bollinger J, Sugarman J, Smith A, Thomas M, Coakley M, Timpone J, Stucke A, Haydel B, Dieter R, Klein E, Neumann H, Gallon L, Goudy L, Callegari M, Marrazzo I, Jackson T, Pruett T, Farnsworth M, Locke J, Mompoint-Williams D, Basinger K, Mekeel K, Nguyen P, Kwan J, Srisengfa T, Chin-Hong P, Rogers R, Simkins J, Munoz C, Dunn T, Sawinski D, Silveira F, Hughes K, Pakstis D, Nagy J, Baldecchi M, Muthukumar T, Eddie M, Robb K, Salsgiver E, Witting B, Azar M, Villanueva M, Formica R, Tomlin R. National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases 2021, 74: 2010-2019. PMID: 34453519, PMCID: PMC9187316, DOI: 10.1093/cid/ciab743.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistance mutationsHIV-positive donorsHIV drug resistance mutationsViral loadMedian CD4 T-cell countCD4 T-cell percentagesHIV Organ Policy Equity (HOPE) ActCD4 T-cell countNonnucleoside reverse transcriptase inhibitorIntegrase strand transfer inhibitorsDonor-derived infectionInhibitor-based regimensT cell percentageT-cell countsHepatitis C viremiaHIV viral loadCD4 T cellsDeceased organ donorsReverse transcriptase inhibitorFalse-positive test resultsStrand transfer inhibitorsC viremiaVirologic characteristicsClinical characteristics
2016
Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
Kulkarni S, Kirkiles‐Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseComplement C5Complement Inactivating AgentsEarly Intervention, EducationalFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedPilot ProjectsPrognosisRisk FactorsTissue DonorsTransplant RecipientsYoung AdultConceptsDe novo donor-specific antibodiesComplement inhibitionTreatment groupsNovo donor-specific antibodiesAntibody-Mediated InjuryC1q-positive patientsDonor-specific antibodiesKidney transplant recipientsPrimary end pointEndothelial cell injuryMo of observationEculizumab therapyEculizumab treatmentHumoral injuryTransplant recipientsKidney transplantRenal functionKidney functionChronic settingEGFR trajectoriesTreatment periodCell injuryPatientsEnd pointPercentage change